BPA for ryplazim
Active Awarded Last action
- Contract number
- 36E79723A0007
- Awardee
-
Kedrion Biopharma Inc. UEI UN3DCKKLHSE7
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- VA797P12Q0002 Solicitation number
- Last date to order 97% complete
- IDV ceiling
- $6,358,550.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
This Blanket Purchase Agreement is a single award contract issued by the Department of Veterans Affairs National Acquisition Center to Kedrion Biopharma Inc. for the supply of Ryplazim, a specialized plasma-derived pharmaceutical therapy indicated for the treatment of plasminogen deficiency type 1. The contract, established under GSA Schedule 61-IB (Pharmaceuticals and Drugs), carries a ceiling value of $6,358,550 and extends through December 5, 2026. No set-aside provisions were applied to this award. Kedrion Biopharma, a manufacturer of plasma derivatives used to address rare and chronic conditions including hemophilia and immune deficiencies, was selected as the sole source provider for this critical therapeutic product. The BPA mechanism provides the Department of Veterans Affairs with a streamlined contracting vehicle to ensure consistent access to Ryplazim for veteran populations requiring treatment for this rare bleeding disorder.
The contract includes provision for 2026 public law pricing updates, ensuring that the pricing structure remains compliant with applicable legislative requirements throughout the performance period. As a Blanket Purchase Agreement, this contract functions as an indefinite-quantity vehicle under which the VA may issue delivery orders to obtain Ryplazim as needed to support veteran healthcare services. The single award structure reflects the specialized nature of the product and the limited number of manufacturers capable of supplying plasma-derived therapeutics meeting federal pharmaceutical standards. This arrangement enables the VA to efficiently procure specialty pharmaceutical products while ensuring access to medically necessary treatments for veterans with rare bleeding disorders and related plasma protein deficiency conditions.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79723A0007?
36E79723A0007 was awarded to Kedrion Biopharma Inc. by National Acquisition Center (Headquarters) on December 6, 2022.
How much is contract 36E79723A0007 worth?
36E79723A0007's own ceiling is $6,358,550.
Who can order from contract 36E79723A0007?
36E79723A0007 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36E79723A0007 under another contract?
Yes. 36E79723A0007 is a blanket purchase agreement under 36F79719D0242, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36E79723A0007 competed?
The extent of competition for 36E79723A0007 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV